CGC
Canopy Growth Corp
$0.93
-0.03 (-2.73%)
At close · Jul 16
Going-concern doubt
— flagged Jun 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In the past, we have identified conditions and events that raised substantial doubt about our ability to continue as a going concern and it is possible that we may identify conditions and events in the future that raise substantial doubt about our ability to continue as a going concern.”View the 10-K filed Jun 15, 2026
Market Cap
$391.42M
Shares
422,154,892
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.93
Open$0.95
Day$0.92–0.97
52W$0.84–2.38
Avg vol 30d5.4M
Short int23.7M · 5.6% float · 5.2d
Short vol57%
Last earningsJun 15, 2026
DataJan 2020–Jul 2026
Filing10-K · Jun 15
Up next
Next earnings call
Sep 14, 2026
Est · unconfirmed
· in 8 wks
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Jun 15, 2026
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−9%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−21%
trailing
YTD return
−19%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
17 of 225 funds reported for Jun 30 · net -264 sh shares · +1 new
Insider flow
Distributing
Net -$239.0K over 90 days · 100% sells
Short interest
Falling
5.62% of float · ▼ -0.7% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
225 holders — near 3-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
102%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−9%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
17 of 225 funds reported for Jun 30 · net -264 sh shares · +1 new
Insider flow
Distributing
Net -$239.0K over 90 days · 100% sells
Short interest
Falling
5.62% of float · ▼ -0.7% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
225 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $1 · 5%
52-wk high $2
vs 200-day avg -19%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted gross margin non-GAAP | 27% | Q4 FY2026 | — |
| Cannabis adjusted gross margin non-GAAP | 26% | Q4 FY2026 | — |
| Adjusted EBITDA loss non-GAAP | -3M | Q3 FY2026 | — |
| Annualized savings | 29M | Since March 1, 2025 | — |
| Free cash outflow non-GAAP | -19M | Q3 FY2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGC
this stock
Canopy Growth Corp
|
$391.42M | -18.7% | — | — | 5.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.43B | +7.3% | — | — | 0.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
GALDY
Galderma Group AG/ADR
|
$49.13B | -0.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.52B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGC | -4.8% | -3.2% | -20.8% | -2.4% | -18.7% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -4.7% | -3.3% | -29.7% | -3.0% | -28.8% |